10-Q: SELLAS Life Sciences Reports Third Quarter 2024 Results, Provides Clinical Trial Updates

SELLAS Life Sciences reported a net loss of $24.1 million for the nine months ended September 30, 2024, while providing updates on its clinical programs for GPS and SLS009.

Summary

• SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics.
• The company's lead product candidate, galinpepimut-S (GPS), targets the WT1 protein, which is present in many cancer types.
• SELLAS' second product candidate is SLS009, a CDK9 inhibitor, licensed from GenFleet Therapeutics.
• For the nine months ended September 30, 2024, the company reported a net loss of $24.1 million, compared to a net loss of $29.2 million for the same period in 2023.
• Research and development expenses decreased to $14.7 million for the nine months ended September 30, 2024, from $18.9 million in the same period of 2023.
• General and administrative expenses decreased to $9.9 million for the nine months ended September 30, 2024, from $10.8 million in the same period of 2023.
• The company had cash and cash equivalents of approximately $21.0 million and restricted cash and cash equivalents of $0.1 million as of September 30, 2024.
• The company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months.
• The company will require substantial additional financing to commercially develop any current or future product candidates.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive clinical trial updates and regulatory designations, the company's financial situation and need for additional funding raise concerns. The ongoing arbitration also adds uncertainty.

Positives

• The IDMC recommended the REGAL trial continue without modifications, indicating positive progress.
• The Phase 2a trial of SLS009 showed promising response rates, particularly in patients with ASXL1 mutations.
• The company has secured multiple Orphan Drug and Rare Pediatric Disease designations for both GPS and SLS009.
• SELLAS successfully raised significant capital through multiple offerings in 2024.
• The company has a partnership with GenFleet for SLS009 in Greater China.

Negatives

• The company has incurred recurring losses and negative cash flows from operations.
• SELLAS has an accumulated deficit of $241.4 million as of September 30, 2024.
• The company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months.
• SELLAS is involved in an arbitration proceeding against 3D Medicines regarding milestone payments.
• The company is dependent on additional funding to support its planned operating activities through profitability.

Risks

• The company's future success is dependent on the successful development, approval, and commercialization of its product candidates.
• There is a risk that the company may not be able to obtain additional funding on a timely basis.
• The company's clinical trials may not yield positive results.
• The company may face challenges in obtaining regulatory approvals for its product candidates.
• The company is subject to risks associated with preclinical or clinical development and trials.
• The company is subject to changes in applicable laws or regulations.
• The company is subject to the impact of natural disasters, including climate change, and the impact of health epidemics on its business.
• The company is subject to the possibility that it may be adversely affected by other economic, business, and/or competitive factors.

Future Outlook

The company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months and will require substantial additional financing to commercially develop any current or future product candidates. The company anticipates that research and development expenses will increase in the future as it continues to advance the development of GPS and SLS009.

Management Comments

• The company's management continues to evaluate different strategies to obtain the required funding for future operations.
• The company continues to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to the company's product candidates.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on novel cancer therapeutics. The development of immunotherapies and targeted therapies like GPS and SLS009 aligns with current trends in oncology research. The company's focus on specific biomarkers, such as ASXL1 mutations, reflects a growing trend towards personalized medicine in cancer treatment.

Comparison to Industry Standards

• SELLAS's approach to targeting the WT1 protein with GPS is similar to other companies developing peptide-based immunotherapies, such as Immatics and Gritstone Bio, but with a focus on different cancer types.
• The development of SLS009 as a CDK9 inhibitor places SELLAS in competition with other companies developing similar drugs, such as Syros Pharmaceuticals and Constellation Pharmaceuticals, but with a focus on a highly selective molecule.
• The clinical trial results for SLS009, particularly the response rates in patients with ASXL1 mutations, are promising compared to standard treatments for r/r AML, such as venetoclax and azacitidine alone.
• The company's financial position, with a significant accumulated deficit and the need for additional funding, is not uncommon for clinical-stage biopharmaceutical companies, but it highlights the importance of successful clinical trial outcomes and strategic partnerships.

Legal Proceedings

• The company commenced a binding arbitration proceeding against 3D Medicines regarding milestone payments and development efforts.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and the need for additional funding.
• Employees are impacted by the company's financial situation and potential changes in operations.
• Patients are impacted by the progress of clinical trials and the potential availability of new treatments.
• The company's suppliers and creditors are impacted by the company's financial stability.

Next Steps

• The company will continue to advance the development of GPS and SLS009.
• The company will conduct the interim analysis of the REGAL study by the fourth quarter of 2024.
• The company will continue to enroll patients in the Phase 2a clinical trial of SLS009 in r/r AML.
• The company will report relevant data from the PIVOT program for SLS009 in the fourth quarter of 2024.
• The company will continue to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to its product candidates.
• The company will seek additional funding to support its operations.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, GPS, SLS009, CDK9 inhibitor, AML, Acute Myeloid Leukemia, Clinical Trial, Orphan Drug Designation, Rare Pediatric Disease Designation, Immunotherapy, Oncology, Biopharmaceutical, ASXL1 mutation, Venetoclax, Azacitidine